Australia's ANZ Group on Friday said it would take a A$1.11 billion ($721.28 million) after-tax profit hit in the second half ...
MarketBeat on MSN
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
Investing in biotechnology often feels like navigating a minefield. A single failed clinical trial can decimate a stock, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results